Targeting the IGF1 axis in cancer proliferation

Author： Bruchim Ilan   Attias Zohar   Werner Haim  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.13, Iss.10, 2009-10, pp. : 1179-1192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The IGF Axis in Prostate Cancer

By  

Current Pharmaceutical Design, Vol. 13, Iss. 7, 2007-03 ,pp. : 719-727

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

By Buck Elizabeth   Mulvihill Mark  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 605-621

Informa Healthcare

Access to resources Recommend Favorite

The GH/IGF-1 Axis in Chronic Heart Failure

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 1, 2013-01 ,pp. : 76-91

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting IGF-1 signaling pathways in gynecologic malignancies

By Bruchim Ilan   Werner Haim  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 3, 2013-03 ,pp. : 307-320

Informa Healthcare

Access to resources Recommend Favorite

Atrasentan: targeting the endothelin axis in prostate cancer

By Jimeno Antonio   Carducci Michael  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. : 1631-1640

Informa Healthcare

Access to resources Recommend Favorite